Pharsight

Orilissa generic

Orilissa is an endometriosis management drug owned by Abbvie Inc. It contains the active ingredient elagolix sodium and was first authorized for market use on 23 July, 2018. It is available in tablet; oral dosage forms and has a total of 6 drug patents, none of which have expired.

When will Orilissa generic be available?

Drug patent challenges can be filed against Orilissa from July 23, 2022. The generic version of Orilissa is possible to be released after September 1, 2036, due to the expiration of the last patent. It's important to note that this generic release date can change if there are any legal battles or if any new patents are filed.

Orilissa uses

Orilissa is used for the management of moderate to severe pain associated with endometriosis. The effectiveness of Orilissa is due to its active ingredient, Elagolix, which can be used in different dosages for various scenarios. This includes using 150mg elagolix while co-administering rifampin or ketoconazole, as well as using 200 mg bid for 6 months to manage moderate to severe pain, reduce dysmenorrhea and non-menstrual pelvic pain, or manage pain in premenopausal women having dyspareunia associated with endometriosis.

Orilissa patent expiration

Orilissa holds 6 patents with none expired. The patents primarily relate to the methods of using Elagolix and Gonadotropin-releasing hormone receptor antagonists for treating different forms of endometriosis. The last patent is set to expire on September 1, 2036. You can file a drug patent challenge against Orilissa starting from July 23, 2022. For more information about when Orilissa generic will be available, see below for the details of the patent:

Orilissa dosage

Want to ask something?